Cogent Biosciences, Inc. COGT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -85.7%-12.0pp | -73.7%+21.7pp | -95.4%+12.2pp | -107.6%-23.5pp | -84%+15.5pp | |
| Return on invested capital | -147.2%-17.9pp | -129.2%+0.8pp | -130%+23.2pp | -153.2%+19.0pp | -172.1%-33.8pp | |
| Liquidity | ||||||
| Current ratio | 15.1×+0.9× | 14.2×+7.9× | 6.4×+2.2× | 4.2×-0.9× | 5.1×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×-0.2× | 0.2×-0.2× | 0.4×+0.3× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.75-24.1% | $4.94+125% | $2.20+62.4% | $1.35-29.9% | $1.93-21.7% | |
| Valuation | ||||||
| Market capitalization | $6.25B+14.6% | $5.45B+172% | $2.01B+143% | $824.32M+20.9% | $681.96M-20.8% | |
| Price / book | 10.3×+1.7× | 8.6×+1.9× | 6.6×+1.3× | 5.3×+2.2× | 3.1×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cogent Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cogent Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
